{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:29:43Z","timestamp":1790278183640,"version":"4.1.0"},"reference-count":101,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2020,12,1]]},"DOI":"10.1080\/13543784.2020.1839047","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T17:44:33Z","timestamp":1603129473000},"page":"1323-1338","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":23,"title":["A case study of foliglurax, the first clinical mGluR4 PAM for symptomatic treatment of Parkinson\u2019s disease: translational gaps or a failing industry innovation model?"],"prefix":"10.1080","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5944-383X","authenticated-orcid":false,"given":"Dario","family":"Doller","sequence":"first","affiliation":[{"name":"Alcyoneus ScienceWorks, LLC., NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3730-1395","authenticated-orcid":false,"given":"Anton","family":"Bespalov","sequence":"additional","affiliation":[{"name":"Partnership for Assessment and Accreditation of Scientific Practice, Heidelberg, Germany"},{"name":"Valdman Institute of Pharmacology, Pavlov Medical University, St. Petersburg, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Miller","sequence":"additional","affiliation":[{"name":"Ventral Stream Consulting LLC., IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Pietraszek","sequence":"additional","affiliation":[{"name":"Partnership for Assessment and Accreditation of Scientific Practice, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Kalinichev","sequence":"additional","affiliation":[{"name":"Addex Therapeutics, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,11,11]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-019-00074-z"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1166"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1813"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.55915"},{"key":"cit0005","unstructured":"Rigor and Reproducibility. [cited 2020\u00a0May\u00a022]. https:\/\/www.nih.gov\/research-training\/rigor-reproducibility\/principles-guidelines-reporting-preclinical-research"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2011.12.020"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1197"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf2608"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.244"},{"key":"cit0010","unstructured":"Lundbeck reports headline results from phase IIa AMBLED study of foliglurax in Parkinson\u2019s disease. [cited 2020\u00a0Apr\u00a03]. https:\/\/investor.lundbeck.com\/releases"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.136"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2018.03.003"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2018.1443076"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.37.1.205"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2010.10.022"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9861(19990428)407:1<33::AID-CNE3>3.0.CO;2-G"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(01)00591-7"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-006-0266-5"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2012.05.017"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(01)00485-7"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1016\/S1042-3680(18)30261-4"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.3171\/jns.1996.84.2.0194"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(99)00583-7"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.21-03-01033.2001"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1152\/jn.1995.74.4.1800"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-2236(97)01151-X"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.20-22-08559.2000"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.23-18-07218.2003"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1096\/fj.09-131789"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1835724100"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1517\/17460441.2012.660914"},{"issue":"10","key":"cit0032","first-page":"949","volume":"9","author":"Lindsley CW","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1517\/13543770903551295"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.4155\/fmc.09.38"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.2174\/1568026614666140902143830"},{"key":"cit0036","first-page":"441","volume":"47","author":"Conn PJ","year":"2012","journal-title":"Annu Rep Med Chem"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(03)00271-5"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.11.104"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.156380"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1021\/cn9000318"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00991"},{"key":"cit0042","unstructured":"Schann S, Mayer S, Morice C, et al. Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors. WO2011051478A1, May 5, 2011."},{"key":"cit0043","unstructured":"Charvin D, Manteau B, Pomel V, et al. Novel Chromone Oxime Derivative and Its Use as Allosteric Modulator of Metabotropic Glutamate Receptors."},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.6b00273"},{"key":"cit0045","unstructured":"Moving beyond rules: the development of a central nervous system multiparameter optimization (cns mpo) approach to enable alignment of druglike properties \u2013 PubMed. [cited 2020\u00a0May\u00a021]. https:\/\/pubmed.ncbi.nlm.nih.gov\/22778837\/"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(96)00423-1"},{"key":"cit0047","unstructured":"Calculation of molecular properties. [cited 2020\u00a0Apr\u00a026]. https:\/\/www.molinspiration.com\/services\/properties.html"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1602\/neurorx.2.4.541"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.9b00062"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1124\/pr.54.2.323"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2017.03.084"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01651"},{"issue":"4","key":"cit0053","first-page":"923","volume":"50","author":"Gomeza J","year":"1996","journal-title":"Mol Pharmacol"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)50280-0"},{"issue":"1","key":"cit0055","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/acs.jmedchem.8b00994","volume":"62","author":"Bollinger SR","year":"2019","journal-title":"J Med Chem"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.04.041"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.187443"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.196063"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1021\/jm200956q"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2010.06.078"},{"key":"cit0061","unstructured":"Charvin D, Di Paolo T, Bezard E, et al. Foliglurax: from mGlu4 receptors to patients with Parkinson\u2019s disease; Lisbon, Portugal, 2019; p Abs S35\u201303."},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27462"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2016.07.012"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27486"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2015.02.023"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2012.03.022"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-2011-11066"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-191824"},{"key":"cit0069","volume-title":"Discovery, characterization and anti-Parkinsonian effect of a Novel mGluR4 PAM chemical series","volume":"71","author":"Blayo A-L","year":"2018"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2015.11.015"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1021\/jm501245b"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1016\/0896-6273(92)90118-W"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.047092"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1124\/mol.117.110114"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2014.245"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-018-1257-0"},{"key":"cit0077","unstructured":"Research, C. for D. E. and. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. [cited 2020\u00a0May\u00a026]. http:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.8b00426"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2018.10.050"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2013.06.001"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-150700"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27131"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18339-1"},{"key":"cit0084","unstructured":"CDER Clinical Review, NDA 022075. [cited 2020 Oct 4]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/022075Orig1s000MedR.pdf."},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30396-5"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21315"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000313834.22171.17"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2012.04.013"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1021\/ml400338f"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2018.05.001"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12142"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1007\/BF01345235"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2015.10.007"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00201"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.176628"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2015.11.010"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.6b00036"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.2174\/1570180815666181017131349"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127212"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01426.x"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.88"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2020.1839047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T05:34:54Z","timestamp":1620452094000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2020.1839047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,11]]},"references-count":101,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,1]]}},"alternative-id":["10.1080\/13543784.2020.1839047"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2020.1839047","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-07-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}